LUDIOMIL
LOE ApproachingNDAORALTABLET
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUDIOMIL is an oral tablet small-molecule antidepressant approved in 1980 by Novartis under NDA. The drug's mechanism of action and specific indications are not detailed in available records, but it represents a legacy psychiatric medication from the tricyclic or related class era.
LOE Approaching
As LOE approaches, commercial teams are likely managing a declining revenue base with minimal headcount expansion; focus shifts to defending residual market share and optimizing operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LUDIOMIL offers limited career growth prospects due to its LOE status and minimal linked job openings. Roles are largely defensive and operationally focused, best suited for professionals seeking stability in a mature portfolio asset rather than career acceleration.
Medical Science LiaisonBrand Manager
Worked on LUDIOMIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.